BioAge Labs Q2 2026: $381M Cash Funds Pipeline Through 2029, Phase 2 Data in H2 2026

summarizeSummary

BioAge Labs reported Q2 2026 financials with $381.3 million in cash, funding operations through 2029. The Phase 2 QUELL-CV trial for BGE-102 is underway with data expected in H2 2026, a key catalyst after the stock's recent 61% drop on competitor failure.

check_boxKey Events · Earnings and Guidance · BIOA

• Q2 2026 Financial Results

  Collaboration revenue $2.4M, R&D expenses $24.4M (up $4.6M YoY driven by BGE-102 program), net loss $26.1M ($0.58/share). Cash, equivalents, and marketable securities totaled $381.3M as of June 30, 2026.

• Cash Runway Through 2029

  Management estimates existing cash will fund operations and capital expenses through 2029, covering multiple clinical readouts including Phase 2 QUELL-CV and Phase 1b/2a QUELL-DME.

• Phase 2 QUELL-CV Trial Underway

  First participant dosed in June 2026; randomized, placebo-controlled trial of BGE-102 in ~160 adults with obesity and elevated inflammation. Topline data expected in H2 2026.

• QUELL-DME Trial Planned Mid-2026

  Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema to initiate mid-2026, with data anticipated mid-2027.

auto_awesomeAnalysis · BIOA · Life Sciences

BioAge Labs reported Q2 2026 results with a strong cash position of $381.3 million, extending its runway through 2029 — well past key catalysts. The company dosed the first patient in the Phase 2 QUELL-CV trial for its lead NLRP3 inhibitor BGE-102, with topline data expected in the second half of 2026. A second proof-of-concept trial in diabetic macular edema is planned to start mid-2026. These milestones come against a backdrop of a 61% stock crash in late July after a competitor's NLRP3 inhibitor failed a Phase 3 trial, making the upcoming BGE-102 readout a critical value driver. The cash position removes near-term financing risk, but the stock's recovery hinges on positive Phase 2 data.